SI2753609T1 - Benzotiazolonska spojina - Google Patents

Benzotiazolonska spojina

Info

Publication number
SI2753609T1
SI2753609T1 SI201230841A SI201230841A SI2753609T1 SI 2753609 T1 SI2753609 T1 SI 2753609T1 SI 201230841 A SI201230841 A SI 201230841A SI 201230841 A SI201230841 A SI 201230841A SI 2753609 T1 SI2753609 T1 SI 2753609T1
Authority
SI
Slovenia
Prior art keywords
benzothiazolone compound
benzothiazolone
compound
Prior art date
Application number
SI201230841A
Other languages
English (en)
Inventor
Jun Cao
Bernhard Erb
Robin Alec Fairhurst
Arnaud Grandeury
Shinji Hatakeyama
Magdalena Koziczak-Holbro
Xinzhong Lai
Philipp Lustenberger
Bernd Riebesehl
Nicola Tufilli
Thomas Ullrich
Xiang Wu
Jianguang Zhou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47010668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2753609(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2753609T1 publication Critical patent/SI2753609T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08Acetic acid
    • C07C53/10Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Cosmetics (AREA)
SI201230841A 2011-09-06 2012-09-05 Benzotiazolonska spojina SI2753609T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011079379 2011-09-06
EP12770249.6A EP2753609B1 (en) 2011-09-06 2012-09-05 Benzothiazolone compound
PCT/IB2012/054580 WO2013035047A1 (en) 2011-09-06 2012-09-05 Benzothiazolone compound

Publications (1)

Publication Number Publication Date
SI2753609T1 true SI2753609T1 (sl) 2017-03-31

Family

ID=47010668

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201230841A SI2753609T1 (sl) 2011-09-06 2012-09-05 Benzotiazolonska spojina

Country Status (38)

Country Link
US (6) US8933108B2 (sl)
EP (1) EP2753609B1 (sl)
JP (2) JP6130835B2 (sl)
KR (2) KR101800140B1 (sl)
CN (2) CN106187942B (sl)
AP (1) AP3830A (sl)
AR (1) AR087787A1 (sl)
AU (1) AU2013200422C1 (sl)
BR (1) BR112014004732A2 (sl)
CA (1) CA2845766A1 (sl)
CL (1) CL2014000493A1 (sl)
CO (1) CO6900147A2 (sl)
CR (1) CR20140114A (sl)
CU (1) CU24303B1 (sl)
CY (1) CY1118585T1 (sl)
DK (1) DK2753609T3 (sl)
EA (1) EA022909B1 (sl)
ES (1) ES2615052T3 (sl)
GT (1) GT201400042A (sl)
HR (1) HRP20170075T1 (sl)
HU (1) HUE030530T2 (sl)
IL (1) IL231235A (sl)
JO (1) JO3192B1 (sl)
LT (1) LT2753609T (sl)
MX (1) MX345405B (sl)
MY (1) MY163301A (sl)
PE (1) PE20141993A1 (sl)
PL (1) PL2753609T3 (sl)
PT (1) PT2753609T (sl)
RS (1) RS55468B1 (sl)
SG (1) SG2014013114A (sl)
SI (1) SI2753609T1 (sl)
TN (1) TN2014000060A1 (sl)
TW (1) TWI555738B (sl)
UA (1) UA114295C2 (sl)
UY (1) UY34312A (sl)
WO (1) WO2013035047A1 (sl)
ZA (2) ZA201401112B (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
EA029946B1 (ru) * 2012-08-30 2018-06-29 Новартис Аг СОЛИ СОЕДИНЕНИЯ БЕНЗОТИАЗОЛОНА В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРОВ
WO2014076162A1 (en) 2012-11-19 2014-05-22 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
SG11201505544RA (en) * 2013-02-28 2015-09-29 Novartis Ag Formulation comprising benzothiazolone compound
US10967119B1 (en) 2019-04-01 2021-04-06 Azizi Bilal Wearable medication injecting device

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149089T1 (de) * 1987-09-15 1997-03-15 Rowett Research Inst Anwendungsgebiete von beta-adrenergenen agonisten
US20070082918A1 (en) * 1993-11-02 2007-04-12 Naftchi N E Neurologically active compounds and compounds with multiple activities
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1999009018A1 (fr) 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha DERIVES DE BENZOTHIAZOLONE PRESENTANT UNE ACTIVITE SELECTIVE D'AGONISTE DU RECEPTEUR β2
EP1144387A1 (en) 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6872723B2 (en) * 2002-01-28 2005-03-29 Wyeth Stabilized difloxacin injectable solution
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
MXPA05010316A (es) * 2003-03-26 2005-11-17 Pharmacia & Upjohn Co Llc Procedimiento para producir alcoholes y aminas enriquecidos enantiomericamente.
US7745462B2 (en) * 2003-04-04 2010-06-29 Novartis Ag Quinoline-2-one derivatives for the treatment of airways diseases
CN1798733A (zh) 2003-06-10 2006-07-05 凯利普西斯公司 作为组蛋白脱乙酰基酶抑制剂的疾病治疗用羰基化合物
JP2007503472A (ja) * 2003-06-10 2007-02-22 カリプシス・インコーポレーテッド 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物
JP2009514779A (ja) 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
JP2009513531A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
JP4851937B2 (ja) 2003-11-21 2012-01-11 セラヴァンス, インコーポレーテッド β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ2受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
GB0402797D0 (en) * 2004-02-09 2004-03-10 Novartis Ag Organic compounds
JP2007537187A (ja) 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
TW200740781A (en) 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
WO2007086078A2 (en) 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
PL1986633T3 (pl) 2006-02-10 2015-01-30 Summit Oxford Ltd Leczenie dystrofii mięśniowej Duchenne'a
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
US20100168245A1 (en) * 2006-08-10 2010-07-01 Wainer Irving W Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
EP2170396B1 (en) 2007-08-03 2016-12-21 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) 2008-12-18 2009-01-28 Astrazeneca Ab New combination
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
EA029946B1 (ru) * 2012-08-30 2018-06-29 Новартис Аг СОЛИ СОЕДИНЕНИЯ БЕНЗОТИАЗОЛОНА В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРОВ
SG11201505544RA (en) 2013-02-28 2015-09-29 Novartis Ag Formulation comprising benzothiazolone compound

Also Published As

Publication number Publication date
US20150336914A1 (en) 2015-11-26
NZ621089A (en) 2015-07-31
AP3830A (en) 2016-09-30
TN2014000060A1 (en) 2015-07-01
TWI555738B (zh) 2016-11-01
CN103781771B (zh) 2016-08-24
HRP20170075T1 (hr) 2017-03-24
WO2013035047A1 (en) 2013-03-14
ES2615052T3 (es) 2017-06-05
JP2014525472A (ja) 2014-09-29
MX345405B (es) 2017-01-30
PL2753609T3 (pl) 2017-05-31
TW201317221A (zh) 2013-05-01
HUE030530T2 (en) 2017-05-29
CY1118585T1 (el) 2017-07-12
CN103781771A (zh) 2014-05-07
BR112014004732A2 (pt) 2017-03-28
MY163301A (en) 2017-09-15
KR101628585B1 (ko) 2016-06-08
GT201400042A (es) 2015-02-19
PT2753609T (pt) 2017-02-08
JP6130835B2 (ja) 2017-05-17
KR20140057382A (ko) 2014-05-12
US20180140582A1 (en) 2018-05-24
IL231235A (en) 2017-09-28
PE20141993A1 (es) 2014-12-17
US8933108B2 (en) 2015-01-13
CN106187942A (zh) 2016-12-07
UA114295C2 (uk) 2017-05-25
CN106187942B (zh) 2020-06-26
SG2014013114A (en) 2014-07-30
ZA201401112B (en) 2016-01-27
EP2753609B1 (en) 2016-11-09
AU2013200422C1 (en) 2015-01-15
KR20160038079A (ko) 2016-04-06
RS55468B1 (sr) 2017-04-28
CO6900147A2 (es) 2014-03-20
JP6340103B2 (ja) 2018-06-06
CU24303B1 (es) 2018-01-10
AP2014007462A0 (en) 2014-02-28
EA022909B1 (ru) 2016-03-31
DK2753609T3 (en) 2017-02-06
JP2017132781A (ja) 2017-08-03
KR101800140B1 (ko) 2017-11-21
US20160279107A1 (en) 2016-09-29
EA201490573A1 (ru) 2014-06-30
AU2013200422A1 (en) 2013-03-21
CL2014000493A1 (es) 2014-10-03
CA2845766A1 (en) 2013-03-14
AR087787A1 (es) 2014-04-16
IL231235A0 (en) 2014-04-30
ZA201500790B (en) 2017-04-26
US10251868B2 (en) 2019-04-09
US20130245080A1 (en) 2013-09-19
US20150094346A1 (en) 2015-04-02
MX2014002688A (es) 2014-04-14
LT2753609T (lt) 2017-01-10
UY34312A (es) 2013-04-30
JO3192B1 (ar) 2018-03-08
US20160075670A1 (en) 2016-03-17
AU2013200422B2 (en) 2014-08-07
CR20140114A (es) 2014-05-06
US9913828B2 (en) 2018-03-13
EP2753609A1 (en) 2014-07-16
CU20140028A7 (es) 2014-05-27

Similar Documents

Publication Publication Date Title
ZA201401553B (en) Cyclopropaneamine compound
IL233154A0 (en) compounds
GB201109763D0 (en) Compounds
GB201106395D0 (en) Compounds
GB201106817D0 (en) New compound
ZA201306857B (en) Mesogen-containing compounds
GB201122139D0 (en) Compounds
GB201107197D0 (en) Compounds
EP2725011A4 (en) NEW COMPOUND
EP2708540A4 (en) PYRIMIDO-DIAZEPINONE COMPOUND
ZA201500790B (en) Benzothiazolone compound
GB201122305D0 (en) Novel compound
HK1191326A1 (en) Azaspirodecanone compounds
GB201110938D0 (en) Compounds
GB201105659D0 (en) Compounds
GB201118613D0 (en) Compounds
GB201112987D0 (en) Novel compound
GB201104669D0 (en) Compound
GB201121538D0 (en) Compound
GB201118102D0 (en) Compound
GB201120805D0 (en) Compounds
GB201119745D0 (en) Compounds
GB201119703D0 (en) Compounds
GB201115827D0 (en) Compounds
GB201115829D0 (en) Compounds